首页 > 最新文献

Cardiogenetics最新文献

英文 中文
Pathogenesis, Diagnosis and Risk Stratification in Arrhythmogenic Cardiomyopathy 致心律失常性心肌病的发病机制、诊断和风险分层
IF 0.6 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-12-08 DOI: 10.3390/cardiogenetics11040025
Maria Teresa Florio, Filomena Boccia, E. Vetrano, M. Borrelli, T. Gossios, G. Palmiero
Arrhythmogenic cardiomyopathy (ACM) is a genetically determined myocardial disease associated with sudden cardiac death (SCD). It is most frequently caused by mutations in genes encoding desmosomal proteins. However, there is growing evidence that ACM is not exclusively a desmosome disease but rather appears to be a disease of the connexoma. Fibroadipose replacement of the right ventricle (RV) had long been the hallmark of ACM, although biventricular involvement or predominant involvement of the left ventricle (LD-ACM) is increasingly found, raising the challenge of differential diagnosis with arrhythmogenic dilated cardiomyopathy (a-DCM). A-DCM, ACM, and LD-ACM are increasingly acknowledged as a single nosological entity, the hallmark of which is electrical instability. Our aim was to analyze the complex molecular mechanisms underlying arrhythmogenic cardiomyopathies, outlining the role of inflammation and autoimmunity in disease pathophysiology. Secondly, we present the clinical tools used in the clinical diagnosis of ACM. Focusing on the challenge of defining the risk of sudden death in this clinical setting, we present available risk stratification strategies. Lastly, we summarize the role of genetics and imaging in risk stratification, guiding through the appropriate patient selection for ICD implantation.
致心律失常性心肌病(ACM)是一种与心源性猝死(SCD)相关的遗传性心肌疾病。它最常见的是由编码桥粒蛋白的基因突变引起的。然而,越来越多的证据表明,ACM不仅是一种桥粒病,而且似乎是一种连接细胞瘤疾病。长期以来,右心室(RV)的纤维脂肪替代一直是ACM的标志,尽管越来越多地发现双心室受累或左心室主要受累(LD-ACM),这增加了与致心律失常扩张型心肌病(a-DCM)鉴别诊断的挑战。A-DCM、ACM和LD-ACM越来越被认为是一个单一的疾病学实体,其标志是电不稳定性。我们的目的是分析致心律失常性心肌病的复杂分子机制,概述炎症和自身免疫在疾病病理生理学中的作用。其次,我们介绍了用于ACM临床诊断的临床工具。针对在这种临床环境中定义猝死风险的挑战,我们提出了可用的风险分层策略。最后,我们总结了遗传学和影像学在风险分层中的作用,指导选择合适的ICD植入患者。
{"title":"Pathogenesis, Diagnosis and Risk Stratification in Arrhythmogenic Cardiomyopathy","authors":"Maria Teresa Florio, Filomena Boccia, E. Vetrano, M. Borrelli, T. Gossios, G. Palmiero","doi":"10.3390/cardiogenetics11040025","DOIUrl":"https://doi.org/10.3390/cardiogenetics11040025","url":null,"abstract":"Arrhythmogenic cardiomyopathy (ACM) is a genetically determined myocardial disease associated with sudden cardiac death (SCD). It is most frequently caused by mutations in genes encoding desmosomal proteins. However, there is growing evidence that ACM is not exclusively a desmosome disease but rather appears to be a disease of the connexoma. Fibroadipose replacement of the right ventricle (RV) had long been the hallmark of ACM, although biventricular involvement or predominant involvement of the left ventricle (LD-ACM) is increasingly found, raising the challenge of differential diagnosis with arrhythmogenic dilated cardiomyopathy (a-DCM). A-DCM, ACM, and LD-ACM are increasingly acknowledged as a single nosological entity, the hallmark of which is electrical instability. Our aim was to analyze the complex molecular mechanisms underlying arrhythmogenic cardiomyopathies, outlining the role of inflammation and autoimmunity in disease pathophysiology. Secondly, we present the clinical tools used in the clinical diagnosis of ACM. Focusing on the challenge of defining the risk of sudden death in this clinical setting, we present available risk stratification strategies. Lastly, we summarize the role of genetics and imaging in risk stratification, guiding through the appropriate patient selection for ICD implantation.","PeriodicalId":41330,"journal":{"name":"Cardiogenetics","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2021-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43179337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease MicroRNAs:从垃圾RNA到生命调节因子及其在心血管疾病中的作用
IF 0.6 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-11-29 DOI: 10.3390/cardiogenetics11040023
Federica Amodio, M. Caiazza, F. Fimiani, P. Calabrò, G. Limongelli
MicroRNAs (miRNAs) are single-stranded small non-coding RNA (18–25 nucleotides) that until a few years ago were considered junk RNA. In the last twenty years, they have acquired more importance thanks to the understanding of their influence on gene expression and their role as negative regulators at post-transcriptional level, influencing the stability of messenger RNA (mRNA). Approximately 5% of the genome encodes miRNAs which are responsible for regulating numerous signaling pathways, cellular processes and cell-to-cell communication. In the cardiovascular system, miRNAs control the functions of various cells, such as cardiomyocytes, endothelial cells, smooth muscle cells and fibroblasts, playing a role in physiological and pathological processes and seeming also related to variations in contractility and hereditary cardiomyopathies. They provide a new perspective on the pathophysiology of disorders such as hypertrophy, fibrosis, arrhythmia, inflammation and atherosclerosis. MiRNAs are differentially expressed in diseased tissue and can be released into the circulation and then detected. MiRNAs have become interesting for the development of new diagnostic and therapeutic tools for various diseases, including heart disease. In this review, the concept of miRNAs and their role in cardiomyopathies will be introduced, focusing on their potential as therapeutic and diagnostic targets (as biomarkers).
微小RNA(miRNA)是单链小的非编码RNA(18-25个核苷酸),直到几年前还被认为是垃圾RNA。在过去的二十年里,由于了解了它们对基因表达的影响,以及它们在转录后水平上作为负调控因子的作用,影响信使RNA(mRNA)的稳定性,它们变得更加重要。大约5%的基因组编码miRNA,miRNA负责调节许多信号通路、细胞过程和细胞间通信。在心血管系统中,miRNA控制各种细胞的功能,如心肌细胞、内皮细胞、平滑肌细胞和成纤维细胞,在生理和病理过程中发挥作用,似乎也与收缩性和遗传性心肌病的变化有关。它们为肥大、纤维化、心律失常、炎症和动脉粥样硬化等疾病的病理生理学提供了新的视角。miRNA在病变组织中差异表达,可以释放到循环中,然后进行检测。miRNA在开发包括心脏病在内的各种疾病的新诊断和治疗工具方面变得很有意思。在这篇综述中,将介绍miRNA的概念及其在心肌病中的作用,重点介绍其作为治疗和诊断靶点(作为生物标志物)的潜力。
{"title":"MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease","authors":"Federica Amodio, M. Caiazza, F. Fimiani, P. Calabrò, G. Limongelli","doi":"10.3390/cardiogenetics11040023","DOIUrl":"https://doi.org/10.3390/cardiogenetics11040023","url":null,"abstract":"MicroRNAs (miRNAs) are single-stranded small non-coding RNA (18–25 nucleotides) that until a few years ago were considered junk RNA. In the last twenty years, they have acquired more importance thanks to the understanding of their influence on gene expression and their role as negative regulators at post-transcriptional level, influencing the stability of messenger RNA (mRNA). Approximately 5% of the genome encodes miRNAs which are responsible for regulating numerous signaling pathways, cellular processes and cell-to-cell communication. In the cardiovascular system, miRNAs control the functions of various cells, such as cardiomyocytes, endothelial cells, smooth muscle cells and fibroblasts, playing a role in physiological and pathological processes and seeming also related to variations in contractility and hereditary cardiomyopathies. They provide a new perspective on the pathophysiology of disorders such as hypertrophy, fibrosis, arrhythmia, inflammation and atherosclerosis. MiRNAs are differentially expressed in diseased tissue and can be released into the circulation and then detected. MiRNAs have become interesting for the development of new diagnostic and therapeutic tools for various diseases, including heart disease. In this review, the concept of miRNAs and their role in cardiomyopathies will be introduced, focusing on their potential as therapeutic and diagnostic targets (as biomarkers).","PeriodicalId":41330,"journal":{"name":"Cardiogenetics","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2021-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49129862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Arrhythmogenic Cardiomyopathy—Further Insight into the Clinical Spectrum of Desmoplakin Disease 致心律失常性心肌病-进一步了解Desmoplakin病的临床谱
IF 0.6 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-11-10 DOI: 10.3390/cardiogenetics11040022
J. Simpson, J. Anusas, Denise Oxnard, S. Wright, R. McGowan, C. Coats
Arrhythmogenic cardiomyopathy is a familial heart muscle disease characterized by structural, electrical, and pathological abnormalities. Recognition of left ventricular (LV) involvement in arrhythmogenic right ventricular cardiomyopathy (ARVC) has led to the newer term of arrhythmogenic cardiomyopathy (ACM). We report on a family with autosomal dominant desmoplakin (DSP) related ACM to illustrate the broad clinical spectrum of disease. The importance of evaluation of relatives with cardiac magnetic resonance imaging and consideration of genetic testing in the absence of Task Force diagnostic criteria is discussed. The practical and ethical issues of access to the Guthrie collection for deoxyribonucleic acid (DNA) testing are considered.
心律失常性心肌病是一种以结构、电和病理异常为特征的家族性心肌疾病。认识到左心室(LV)参与致心律失常性右室心肌病(ARVC)导致了新的术语致心律失常性心肌病(ACM)。我们报告了一个常染色体显性desmoplakin (DSP)相关的ACM家族,以说明疾病的广泛临床谱。讨论了在没有工作组诊断标准的情况下,心脏磁共振成像和基因检测评估亲属的重要性。实际和伦理问题的访问格思里收集的脱氧核糖核酸(DNA)测试进行了考虑。
{"title":"Arrhythmogenic Cardiomyopathy—Further Insight into the Clinical Spectrum of Desmoplakin Disease","authors":"J. Simpson, J. Anusas, Denise Oxnard, S. Wright, R. McGowan, C. Coats","doi":"10.3390/cardiogenetics11040022","DOIUrl":"https://doi.org/10.3390/cardiogenetics11040022","url":null,"abstract":"Arrhythmogenic cardiomyopathy is a familial heart muscle disease characterized by structural, electrical, and pathological abnormalities. Recognition of left ventricular (LV) involvement in arrhythmogenic right ventricular cardiomyopathy (ARVC) has led to the newer term of arrhythmogenic cardiomyopathy (ACM). We report on a family with autosomal dominant desmoplakin (DSP) related ACM to illustrate the broad clinical spectrum of disease. The importance of evaluation of relatives with cardiac magnetic resonance imaging and consideration of genetic testing in the absence of Task Force diagnostic criteria is discussed. The practical and ethical issues of access to the Guthrie collection for deoxyribonucleic acid (DNA) testing are considered.","PeriodicalId":41330,"journal":{"name":"Cardiogenetics","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2021-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47859416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of ABC Transporter Gene Expression in Atherosclerosis 动脉粥样硬化中ABC转运蛋白基因表达分析
IF 0.6 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-11-04 DOI: 10.3390/cardiogenetics11040021
S. Kotlyarov, A. Kotlyarova
ABC transporters are a large family of membrane proteins that transport chemically diverse substrates across the cell membrane. Disruption of transport mechanisms mediated by ABC transporters causes the development of various diseases, including atherosclerosis. Methods: A bioinformatic analysis of a dataset from Gene Expression Omnibus (GEO) was performed. A GEO dataset containing data on gene expression levels in samples of atherosclerotic lesions and control arteries without atherosclerotic lesions from carotid, femoral, and infrapopliteal arteries was used for analysis. To evaluate differentially expressed genes, a bioinformatic analysis was performed in comparison groups using the limma package in R (v. 4.0.2) and the GEO2R and Phantasus tools (v. 1.11.0). Results: The obtained data indicate the differential expression of many ABC transporters belonging to different subfamilies. The differential expressions of ABC transporter genes involved in lipid transport, mechanisms of multidrug resistance, and mechanisms of ion exchange are shown. Differences in the expression of transporters in tissue samples from different arteries are established. Conclusions: The expression of ABC transporter genes demonstrates differences in atherosclerotic samples and normal arteries, which may indicate the involvement of transporters in the pathogenesis of atherosclerosis.
ABC转运蛋白是一大家族的膜蛋白,在细胞膜上转运化学多样的底物。ABC转运蛋白介导的转运机制的破坏导致各种疾病的发展,包括动脉粥样硬化。方法:对来自基因表达综合数据库(GEO)的数据集进行生物信息学分析。使用GEO数据集进行分析,该数据集包含颈动脉、股动脉和腘下动脉的动脉粥样硬化病变样本和无动脉粥样硬化病变的对照动脉中的基因表达水平数据。为了评估差异表达的基因,在比较组中使用R中的limma软件包(v.4.0.2)和GEO2R和Phantasus工具(v.1.11.0)进行了生物信息学分析。结果:所获得的数据表明,属于不同亚家族的许多ABC转运蛋白存在差异表达。显示了参与脂质转运的ABC转运蛋白基因的差异表达、多药耐药性机制和离子交换机制。来自不同动脉的组织样本中转运蛋白表达的差异已经确定。结论:ABC转运蛋白基因在动脉粥样硬化样品和正常动脉中的表达存在差异,这可能表明转运蛋白参与了动脉粥样硬化的发病机制。
{"title":"Analysis of ABC Transporter Gene Expression in Atherosclerosis","authors":"S. Kotlyarov, A. Kotlyarova","doi":"10.3390/cardiogenetics11040021","DOIUrl":"https://doi.org/10.3390/cardiogenetics11040021","url":null,"abstract":"ABC transporters are a large family of membrane proteins that transport chemically diverse substrates across the cell membrane. Disruption of transport mechanisms mediated by ABC transporters causes the development of various diseases, including atherosclerosis. Methods: A bioinformatic analysis of a dataset from Gene Expression Omnibus (GEO) was performed. A GEO dataset containing data on gene expression levels in samples of atherosclerotic lesions and control arteries without atherosclerotic lesions from carotid, femoral, and infrapopliteal arteries was used for analysis. To evaluate differentially expressed genes, a bioinformatic analysis was performed in comparison groups using the limma package in R (v. 4.0.2) and the GEO2R and Phantasus tools (v. 1.11.0). Results: The obtained data indicate the differential expression of many ABC transporters belonging to different subfamilies. The differential expressions of ABC transporter genes involved in lipid transport, mechanisms of multidrug resistance, and mechanisms of ion exchange are shown. Differences in the expression of transporters in tissue samples from different arteries are established. Conclusions: The expression of ABC transporter genes demonstrates differences in atherosclerotic samples and normal arteries, which may indicate the involvement of transporters in the pathogenesis of atherosclerosis.","PeriodicalId":41330,"journal":{"name":"Cardiogenetics","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2021-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48749170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Azygos Vein ICD Lead Implantation Lowers Defibrillation Threshold in a Patient with Hypertrophic Cardiomyopathy 奇静脉ICD导联植入降低肥厚性心肌病患者的除颤阈值
IF 0.6 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-10-07 DOI: 10.3390/cardiogenetics11040019
G. Quarta, P. Ferrari, A. Giammarresi, G. Malanchini, C. Leidi, M. Senni, P. De Filippo
A 14-year-old boy with hypertrophic cardiomyopathy (HCM) diagnosed at the age of 1 year and with massive left ventricular hypertrophy suffered an episode of ventricular fibrillation during mild effort. He underwent a dual-chamber implantable cardioverter defibrillator (ICD) implantation. The defibrillation threshold testing (DFT) was ineffective. Subcutaneous multi-coli arrays tunneled into the left postero-lateral position and connected to the superior vena cava (SVC) port of the dual-chamber ICD were added to increase the myocardial mass involved in the defibrillation shock pathway. A new DFT was unsuccessful. The patient was transferred to our hospital for myectomy. An epicardial defibrillation patch was placed on the left ventricular lateral wall, but again, DFT testing was ineffective using the right ventricular (RV) coil to lateral patch as shock pathway. Another epicardial defibrillation patch was then placed on the inferior wall. In this case, DFT testing was effective with a defibrillation pathway between the two patches and the can. In November 2015, a high shock impedance alarm was recorded through remote monitoring, thus compromising the safety of the ICD shock pathway. The patient underwent the implant of a new trans-venous defibrillation coil lead in the azygos vein. After few months, the patient developed symptomatic severe aortic regurgitation and underwent an aortic valve replacement. During the operation, DFT testing was performed and was successful. Our case illustrates that azygous vein ICD lead implantation is efficacious in HCM with massive hypertrophy and high DFT, and prompts further studies to systematically investigate its efficacy in this particular subgroup of the HCM population.
一名14岁男孩在1岁时被诊断为肥厚型心肌病(HCM),并患有严重的左心室肥大,在轻度努力过程中出现了心室颤动。他接受了双腔植入式心律转复除颤器(ICD)植入术。除颤阈值测试(DFT)无效。皮下多大肠杆菌阵列通过隧道进入左后外侧位置,并连接到双腔ICD的上腔静脉(SVC)端口,以增加除颤电击路径中涉及的心肌质量。新的DFT未成功。病人被转移到我们医院进行脊髓切除术。将心外膜除颤贴片放置在左心室侧壁上,但同样,使用右心室(RV)线圈至侧贴片作为电击路径的DFT测试无效。然后在下壁上放置另一块心外膜除颤贴片。在这种情况下,DFT测试在两个贴片和罐子之间的除颤路径下是有效的。2015年11月,通过远程监测记录到高电击阻抗警报,从而危及ICD电击路径的安全性。患者在奇静脉植入了一根新的经静脉除颤线圈导线。几个月后,患者出现症状性严重主动脉瓣反流,并接受了主动脉瓣置换术。在操作过程中,进行了DFT测试并取得了成功。我们的病例表明,奇静脉ICD导线植入治疗肥厚和高DFT的HCM是有效的,并促使进一步的研究系统地研究其在HCM人群的这一特定亚组中的疗效。
{"title":"Azygos Vein ICD Lead Implantation Lowers Defibrillation Threshold in a Patient with Hypertrophic Cardiomyopathy","authors":"G. Quarta, P. Ferrari, A. Giammarresi, G. Malanchini, C. Leidi, M. Senni, P. De Filippo","doi":"10.3390/cardiogenetics11040019","DOIUrl":"https://doi.org/10.3390/cardiogenetics11040019","url":null,"abstract":"A 14-year-old boy with hypertrophic cardiomyopathy (HCM) diagnosed at the age of 1 year and with massive left ventricular hypertrophy suffered an episode of ventricular fibrillation during mild effort. He underwent a dual-chamber implantable cardioverter defibrillator (ICD) implantation. The defibrillation threshold testing (DFT) was ineffective. Subcutaneous multi-coli arrays tunneled into the left postero-lateral position and connected to the superior vena cava (SVC) port of the dual-chamber ICD were added to increase the myocardial mass involved in the defibrillation shock pathway. A new DFT was unsuccessful. The patient was transferred to our hospital for myectomy. An epicardial defibrillation patch was placed on the left ventricular lateral wall, but again, DFT testing was ineffective using the right ventricular (RV) coil to lateral patch as shock pathway. Another epicardial defibrillation patch was then placed on the inferior wall. In this case, DFT testing was effective with a defibrillation pathway between the two patches and the can. In November 2015, a high shock impedance alarm was recorded through remote monitoring, thus compromising the safety of the ICD shock pathway. The patient underwent the implant of a new trans-venous defibrillation coil lead in the azygos vein. After few months, the patient developed symptomatic severe aortic regurgitation and underwent an aortic valve replacement. During the operation, DFT testing was performed and was successful. Our case illustrates that azygous vein ICD lead implantation is efficacious in HCM with massive hypertrophy and high DFT, and prompts further studies to systematically investigate its efficacy in this particular subgroup of the HCM population.","PeriodicalId":41330,"journal":{"name":"Cardiogenetics","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2021-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48326251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Specific Deletion of the FHA Domain Containing SLMAP3 Isoform in Postnatal Myocardium Has No Impact on Structure or Function 产后心肌中含有SLMAP3异构体的FHA结构域的特异性缺失对结构或功能没有影响
IF 0.6 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-10-04 DOI: 10.3390/cardiogenetics11040018
Taha Rehmani, Jana Mlynarova, J. Byers, M. Salih, B. Tuana
Sarcolemmal membrane-associated proteins (SLMAPs) belong to the superfamily of tail-anchored membrane proteins known to regulate diverse biological processes, including protein trafficking and signal transduction. Mutations in SLMAP have been linked to Brugada and defective sodium channel Nav1.5 shuttling. The SLMAP gene is alternatively spliced to generate numerous isoforms, broadly defined as SLMAP1 (~35 kDa), SLMAP2 (~45 kDa) and SLMAP3 (~80–95 kDa), which are highly expressed in the myocardium. The SLMAP3 isoform exhibits ubiquitous expression carrying an FHA domain and is believed to negatively regulate Hippo signaling to dictate cell growth/death and differentiation. Using the αMHC-MerCreMer-flox system to target the SLMAP gene, we specifically deleted the SLMAP3 isoform in postnatal mouse hearts without any changes in the expression of SLMAP1/SLMAP2 isoforms. The in vivo analysis of mice with SLMAP3 cardiac deficiency revealed no significant changes to heart structure or function in young or aged mice without or with isoproterenol-induced stress. SLMAP3-deficient hearts revealed no obvious differences in cardiac size, function or hypertrophic response. Further, the molecular analysis indicated that SLMAP3 loss had a minor impact on sodium channel (Nav1.5) expression without affecting cardiac electrophysiology in postnatal myocardium. Surprisingly, the loss of SLMAP3 did not impact Hippo signaling in postnatal myocardium. We conclude that the FHA domain-containing SLMAP3 isoform has no impact on Hippo signaling or sodium channels in postnatal myocardium, which is able to function and respond normally to stress in its absence. Whether SLMAP1/SMAP2 isoforms can compensate for the loss of SLMAP3 in the affairs of the postnatal heart remains to be determined.
肌鞘膜相关蛋白(SLMAP)属于尾锚定膜蛋白的超家族,已知其调节多种生物过程,包括蛋白质运输和信号转导。SLMAP的突变与Brugada和钠通道Nav1.5穿梭缺陷有关。SLMAP基因交替剪接产生许多亚型,广泛定义为SLMAP1(~35 kDa)、SLMAP2(~45 kDa)和SLMAP3(~80–95 kDa,在心肌中高度表达)。SLMAP3亚型表现出携带FHA结构域的普遍表达,并且被认为负调控Hippo信号传导以支配细胞生长/死亡和分化。使用αMHC-MerCreMer-flox系统靶向SLMAP基因,我们特异性地删除了出生后小鼠心脏中的SLMAP3亚型,而SLMAP1/SLMAP2亚型的表达没有任何变化。对SLMAP3心脏缺陷小鼠的体内分析显示,在没有或有异丙肾上腺素诱导的应激的年轻或老年小鼠中,心脏结构或功能没有显著变化。SLMAP3缺陷心脏在心脏大小、功能或肥大反应方面没有明显差异。此外,分子分析表明,SLMAP3的缺失对钠通道(Nav1.5)的表达影响较小,而不影响出生后心肌的心脏电生理。令人惊讶的是,SLMAP3的缺失并没有影响出生后心肌中Hippo信号传导。我们得出的结论是,含有FHA结构域的SLMAP3亚型对出生后心肌中的Hippo信号传导或钠通道没有影响,后者能够在没有压力的情况下正常发挥功能并对压力做出反应。SLMAP1/SMAP2亚型是否能补偿出生后心脏事务中SLMAP3的损失还有待确定。
{"title":"Specific Deletion of the FHA Domain Containing SLMAP3 Isoform in Postnatal Myocardium Has No Impact on Structure or Function","authors":"Taha Rehmani, Jana Mlynarova, J. Byers, M. Salih, B. Tuana","doi":"10.3390/cardiogenetics11040018","DOIUrl":"https://doi.org/10.3390/cardiogenetics11040018","url":null,"abstract":"Sarcolemmal membrane-associated proteins (SLMAPs) belong to the superfamily of tail-anchored membrane proteins known to regulate diverse biological processes, including protein trafficking and signal transduction. Mutations in SLMAP have been linked to Brugada and defective sodium channel Nav1.5 shuttling. The SLMAP gene is alternatively spliced to generate numerous isoforms, broadly defined as SLMAP1 (~35 kDa), SLMAP2 (~45 kDa) and SLMAP3 (~80–95 kDa), which are highly expressed in the myocardium. The SLMAP3 isoform exhibits ubiquitous expression carrying an FHA domain and is believed to negatively regulate Hippo signaling to dictate cell growth/death and differentiation. Using the αMHC-MerCreMer-flox system to target the SLMAP gene, we specifically deleted the SLMAP3 isoform in postnatal mouse hearts without any changes in the expression of SLMAP1/SLMAP2 isoforms. The in vivo analysis of mice with SLMAP3 cardiac deficiency revealed no significant changes to heart structure or function in young or aged mice without or with isoproterenol-induced stress. SLMAP3-deficient hearts revealed no obvious differences in cardiac size, function or hypertrophic response. Further, the molecular analysis indicated that SLMAP3 loss had a minor impact on sodium channel (Nav1.5) expression without affecting cardiac electrophysiology in postnatal myocardium. Surprisingly, the loss of SLMAP3 did not impact Hippo signaling in postnatal myocardium. We conclude that the FHA domain-containing SLMAP3 isoform has no impact on Hippo signaling or sodium channels in postnatal myocardium, which is able to function and respond normally to stress in its absence. Whether SLMAP1/SMAP2 isoforms can compensate for the loss of SLMAP3 in the affairs of the postnatal heart remains to be determined.","PeriodicalId":41330,"journal":{"name":"Cardiogenetics","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2021-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43571054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Mutations in MYBPC3 and MYH7 in Association with Brugada Type 1 ECG Pattern: Overlap between Brugada Syndrome and Hypertrophic Cardiomyopathy? MYBPC3和MYH7突变与Brugada 1型心电图模式的相关性:Brugada综合征和肥厚型心肌病之间的重叠?
IF 0.6 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-09-09 DOI: 10.3390/cardiogenetics11030016
M. Farnè, C. Balla, A. Margutti, R. Selvatici, M. De Raffele, A. Di Domenico, P. Imbrici, E. De Maria, M. Biffi, M. Bertini, C. Rapezzi, A. Ferlini, F. Gualandi
Brugada syndrome (BrS) is an inherited disorder with high allelic and genetic heterogeneity clinically characterized by typical coved-type ST segment elevation at the electrocardiogram (ECG), which may occur either spontaneously or after provocative drug testing. BrS is classically described as an arrhythmic condition occurring in a structurally normal heart and is associated with the risk of ventricular fibrillation and sudden cardiac death (SCD). We studied five patients with spontaneous or drug-induced type 1 ECG pattern, variably associated with symptoms and a positive family history through a Next Generation Sequencing panels approach, which includes genes of both channelopathies and cardiomyopathies. We identified variants in MYBPC3 and in MYH7, hypertrophic cardiomyopathy (HCM) genes (MYBPC3: p.Lys1065Glnfs*12 and c.1458-1G > A, MYH7: p.Arg783His, p.Val1213Met, p.Lys744Thr). Our data propose that Brugada type 1 ECG may be an early electrocardiographic marker of a concealed structural heart disease, possibly enlarging the genotypic overlap between Brugada syndrome and cardiomyopathies.
Brugada综合征(BrS)是一种具有高度等位基因和遗传异质性的遗传性疾病,临床特征为典型的心电图ST段抬高,可能自发发生,也可能在激发性药物测试后发生。BrS通常被描述为一种发生在结构正常心脏中的心律失常,与心室颤动和心源性猝死(SCD)的风险有关。我们通过下一代测序小组方法研究了五名具有自发或药物诱导的1型心电图模式的患者,这些患者与症状和阳性家族史不同,该方法包括通道病和心肌病的基因。我们在MYBPC3和MYH7中发现了肥厚型心肌病(HCM)基因的变体(MYBPC3:p.Lys1065Glnfs*12和c.1458-1G>A,MYH7:p.Arg783His,p.Val1213Met,p.Lys744Thr)。我们的数据表明,Brugada 1型心电图可能是隐蔽性结构性心脏病的早期心电图标志物,可能会扩大Brugada综合征和心肌病之间的基因型重叠。
{"title":"Mutations in MYBPC3 and MYH7 in Association with Brugada Type 1 ECG Pattern: Overlap between Brugada Syndrome and Hypertrophic Cardiomyopathy?","authors":"M. Farnè, C. Balla, A. Margutti, R. Selvatici, M. De Raffele, A. Di Domenico, P. Imbrici, E. De Maria, M. Biffi, M. Bertini, C. Rapezzi, A. Ferlini, F. Gualandi","doi":"10.3390/cardiogenetics11030016","DOIUrl":"https://doi.org/10.3390/cardiogenetics11030016","url":null,"abstract":"Brugada syndrome (BrS) is an inherited disorder with high allelic and genetic heterogeneity clinically characterized by typical coved-type ST segment elevation at the electrocardiogram (ECG), which may occur either spontaneously or after provocative drug testing. BrS is classically described as an arrhythmic condition occurring in a structurally normal heart and is associated with the risk of ventricular fibrillation and sudden cardiac death (SCD). We studied five patients with spontaneous or drug-induced type 1 ECG pattern, variably associated with symptoms and a positive family history through a Next Generation Sequencing panels approach, which includes genes of both channelopathies and cardiomyopathies. We identified variants in MYBPC3 and in MYH7, hypertrophic cardiomyopathy (HCM) genes (MYBPC3: p.Lys1065Glnfs*12 and c.1458-1G > A, MYH7: p.Arg783His, p.Val1213Met, p.Lys744Thr). Our data propose that Brugada type 1 ECG may be an early electrocardiographic marker of a concealed structural heart disease, possibly enlarging the genotypic overlap between Brugada syndrome and cardiomyopathies.","PeriodicalId":41330,"journal":{"name":"Cardiogenetics","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2021-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45992029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Human SMAD4 Genomic Variants Identified in Individuals with Heritable and Early-Onset Thoracic Aortic Disease. 在可遗传和早发胸主动脉疾病患者中发现人类 SMAD4 基因组变异。
IF 0.6 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-09-01 Epub Date: 2021-08-18 DOI: 10.3390/cardiogenetics11030015
Shreyas A Bhave, Dong-Chuan Guo, Stoyan Angelov, Michael J Bamshad, Deborah A Nickerson, Dianna Milewicz, Mary C Wallingford

Thoracic aortic aneurysms (TAAs) that progress to acute thoracic aortic dissections (TADs) are life threatening vascular events that have been associated with altered transforming growth factor (TGF) β signaling. In addition to TAA, multiple genetic vascular disorders, including hereditary hemorrhagic telangiectasia (HHT), involve altered TGFβ signaling and vascular malformations. Due to the importance of TGFβ, genomic variant databases have been curated for activin receptor-like kinase 1 (ALK1) and endoglin (ENG). This case report details seven variants in SMAD4 that are associated with either heritable or early onset aortic dissections and compares them to pathogenic exon variants in gnomAD v2.1.1. The TAA and TAD variants were identified through whole exome sequencing of 346 unrelated heritable thoracic aortic disease (HTAD) and 355 individuals of early onset (age ≤ 56 years old) of thoracic aortic dissection (ESTAD). An allele frequency filter of less than 0.05% was applied in the Genome Aggregation Database (gnomAD exome v2.1.1) with a combined annotation dependent depletion score (CADD) greater than 20. These seven variants also have a higher REVEL score (>0.2), indicating pathogenic potential. Further in vivo and in vitro analysis is needed to evaluate how these variants affect mRNA stability and SMAD4 protein activity in association with thoracic aortic disease.

胸主动脉瘤(TAA)发展为急性胸主动脉夹层(TAD)是威胁生命的血管事件,与转化生长因子(TGF)β信号的改变有关。除TAA外,包括遗传性出血性毛细血管扩张症(HHT)在内的多种遗传性血管疾病也涉及TGFβ信号的改变和血管畸形。由于 TGFβ 的重要性,基因组变异数据库已针对活化素受体样激酶 1(ALK1)和内切蛋白(ENG)进行了策划。本病例报告详细介绍了 SMAD4 中与遗传性或早发性主动脉夹层相关的七个变异,并将它们与 gnomAD v2.1.1 中的致病外显子变异进行了比较。TAA 和 TAD 变体是通过对 346 例无关的遗传性胸主动脉疾病(HTAD)和 355 例早发(年龄小于 56 岁)胸主动脉夹层(ESTAD)患者的全外显子测序确定的。基因组聚合数据库(gnomAD exome v2.1.1)中的等位基因频率过滤值小于 0.05%,综合注释依赖性损耗分数(CADD)大于 20。这 7 个变异体的 REVEL 评分也较高(>0.2),表明具有致病潜力。需要进一步进行体内和体外分析,以评估这些变异如何影响与胸主动脉疾病相关的 mRNA 稳定性和 SMAD4 蛋白活性。
{"title":"Human <i>SMAD4</i> Genomic Variants Identified in Individuals with Heritable and Early-Onset Thoracic Aortic Disease.","authors":"Shreyas A Bhave, Dong-Chuan Guo, Stoyan Angelov, Michael J Bamshad, Deborah A Nickerson, Dianna Milewicz, Mary C Wallingford","doi":"10.3390/cardiogenetics11030015","DOIUrl":"10.3390/cardiogenetics11030015","url":null,"abstract":"<p><p>Thoracic aortic aneurysms (TAAs) that progress to acute thoracic aortic dissections (TADs) are life threatening vascular events that have been associated with altered transforming growth factor (TGF) β signaling. In addition to TAA, multiple genetic vascular disorders, including hereditary hemorrhagic telangiectasia (HHT), involve altered TGFβ signaling and vascular malformations. Due to the importance of TGFβ, genomic variant databases have been curated for activin receptor-like kinase 1 (<i>ALK1</i>) and endoglin (<i>ENG</i>). This case report details seven variants in <i>SMAD4</i> that are associated with either heritable or early onset aortic dissections and compares them to pathogenic exon variants in gnomAD v2.1.1. The TAA and TAD variants were identified through whole exome sequencing of 346 unrelated heritable thoracic aortic disease (HTAD) and 355 individuals of early onset (age ≤ 56 years old) of thoracic aortic dissection (ESTAD). An allele frequency filter of less than 0.05% was applied in the Genome Aggregation Database (gnomAD exome v2.1.1) with a combined annotation dependent depletion score (CADD) greater than 20. These seven variants also have a higher REVEL score (>0.2), indicating pathogenic potential. Further <i>in vivo</i> and <i>in vitro</i> analysis is needed to evaluate how these variants affect mRNA stability and SMAD4 protein activity in association with thoracic aortic disease.</p>","PeriodicalId":41330,"journal":{"name":"Cardiogenetics","volume":"11 3","pages":"132-138"},"PeriodicalIF":0.6,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495981/pdf/nihms-1761633.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33482499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biventricular Strain Imaging with Cardiac MRI in Genotyped and Histology Validated Amyloid Cardiomyopathy. 基因型和组织学证实的淀粉样心肌病的心脏MRI双心室应变成像。
IF 0.6 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-09-01 Epub Date: 2021-06-30 DOI: 10.3390/cardiogenetics11030011
Abhinay Reddy, Vasvi Singh, Badri Karthikeyan, Leyi Jiang, Silva Kristo, Sharma Kattel, Ram Amuthan, Saraswati Pokharel, Umesh C Sharma

Cardiac amyloidosis (CA) is a common and potentially fatal infiltrative cardiomyopathy. Contrast-enhanced cardiac MRI (CMR) is used as a diagnostic tool. However, utility of CMR for the comprehensive analysis of biventricular strains and strain rates is not reported as extensively as echocardiography. In addition, RV strain analysis using CMR has not been described previously.

Objectives: We sought to study the global and regional indices of biventricular strain and strain rates in endomyocardial biopsy (EMB)-proven, genotyped cases of CA.

Methods: A database of 80 EMBs was curated from 2012 to 2019 based on histology. A total of 19 EMBs positive for CA were subjected to further tissue-characterization with histology, and compared with four normal biopsy specimens. Samples were genotyped for ATTR- or AL-subtypes. Five patients, with both echocardiography and contrast-enhanced CMR performed 72-h apart, were subjected to comprehensive analysis of biventricular strain and strain-rates.

Results: Histology confirmed that the selected samples were indeed positive for cardiac amyloid. Echocardiography showed reduced global and regional left-ventricular (LV) longitudinal strain indices. CMR with tissue-characterization of LV showed global reductions in circumferential, radial and longitudinal strains and strain-rates, following a general trend with the echocardiographic findings. The basal right-ventricular (RV) segments had reduced circumferential strains with no changes in longitudinal strain.

Conclusions: In addition to providing a clinical diagnosis of CA based on contrast clearance-dynamics, CMR can be a potent tool for accurate functional assessment of global and regional changes in strain and strain-rates involving both LV and RV. Further studies are warranted to validate and curate the strain imaging capacity of CMR in CA.

心脏淀粉样变性(CA)是一种常见且具有潜在致命性的浸润性心肌病。对比增强心脏MRI (CMR)被用作诊断工具。然而,CMR对双心室应变和应变率的综合分析的应用并没有像超声心动图那样广泛报道。此外,使用CMR进行RV应变分析以前没有描述过。目的:研究经心肌内膜活检(EMB)证实的ca基因分型病例的双心室应变和应变率的全球和区域指标。方法:基于组织学整理2012年至2019年80例EMB的数据库。共有19例CA阳性的EMBs进行了进一步的组织组织学鉴定,并与4例正常活检标本进行了比较。对样本进行ATTR-或al亚型基因分型。5例患者,超声心动图和增强CMR间隔72小时,对双心室应变和应变率进行综合分析。结果:组织学证实所选样本确实呈心脏淀粉样蛋白阳性。超声心动图显示整体和局部左室纵向应变指数降低。具有左室组织特征的CMR显示环向、径向和纵向应变和应变率整体降低,与超声心动图结果一致。基底右心室(RV)节段的周向应变降低,而纵向应变无变化。结论:除了基于对比清除率动力学提供CA的临床诊断外,CMR还可以作为准确评估左室和右室整体和区域应变和应变率变化的有效工具。需要进一步的研究来验证和管理CMR在CA中的应变成像能力。
{"title":"Biventricular Strain Imaging with Cardiac MRI in Genotyped and Histology Validated Amyloid Cardiomyopathy.","authors":"Abhinay Reddy,&nbsp;Vasvi Singh,&nbsp;Badri Karthikeyan,&nbsp;Leyi Jiang,&nbsp;Silva Kristo,&nbsp;Sharma Kattel,&nbsp;Ram Amuthan,&nbsp;Saraswati Pokharel,&nbsp;Umesh C Sharma","doi":"10.3390/cardiogenetics11030011","DOIUrl":"https://doi.org/10.3390/cardiogenetics11030011","url":null,"abstract":"<p><p>Cardiac amyloidosis (CA) is a common and potentially fatal infiltrative cardiomyopathy. Contrast-enhanced cardiac MRI (CMR) is used as a diagnostic tool. However, utility of CMR for the comprehensive analysis of biventricular strains and strain rates is not reported as extensively as echocardiography. In addition, RV strain analysis using CMR has not been described previously.</p><p><strong>Objectives: </strong>We sought to study the global and regional indices of biventricular strain and strain rates in endomyocardial biopsy (EMB)-proven, genotyped cases of CA.</p><p><strong>Methods: </strong>A database of 80 EMBs was curated from 2012 to 2019 based on histology. A total of 19 EMBs positive for CA were subjected to further tissue-characterization with histology, and compared with four normal biopsy specimens. Samples were genotyped for ATTR- or AL-subtypes. Five patients, with both echocardiography and contrast-enhanced CMR performed 72-h apart, were subjected to comprehensive analysis of biventricular strain and strain-rates.</p><p><strong>Results: </strong>Histology confirmed that the selected samples were indeed positive for cardiac amyloid. Echocardiography showed reduced global and regional left-ventricular (LV) longitudinal strain indices. CMR with tissue-characterization of LV showed global reductions in circumferential, radial and longitudinal strains and strain-rates, following a general trend with the echocardiographic findings. The basal right-ventricular (RV) segments had reduced circumferential strains with no changes in longitudinal strain.</p><p><strong>Conclusions: </strong>In addition to providing a clinical diagnosis of CA based on contrast clearance-dynamics, CMR can be a potent tool for accurate functional assessment of global and regional changes in strain and strain-rates involving both LV and RV. Further studies are warranted to validate and curate the strain imaging capacity of CMR in CA.</p>","PeriodicalId":41330,"journal":{"name":"Cardiogenetics","volume":"11 3","pages":"98-110"},"PeriodicalIF":0.6,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39265587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
A Novel Human Biospecimen Repository for Clinical and Molecular Investigation of Thoracic Aortopathy. 用于胸主动脉病变临床和分子研究的新型人类生物标本库。
IF 0.6 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-09-01 Epub Date: 2021-09-18 DOI: 10.3390/cardiogenetics11030017
Courtney E Vujakovich, Benjamin J Landis

Thoracic aortic aneurysm (TAA) is a heritable aortopathy with significant morbidity and mortality, affecting children and adults. Genetic causes, pathobiological mechanisms, and prognostic markers are incompletely understood. In 2015, the Collaborative Human Aortopathy Repository (CHAR) was created to address these fundamental gaps. Patients with thoracic aortopathy, associated genetic diagnoses, or aortic valve disease are eligible for prospective enrollment. Family members and controls are also enrolled. Detailed clinical and family data are collected, and blood and aortic tissue biospecimens are processed for broad usage. A total of 1047 participants were enrolled. The mean age in 834 affected participants was 47 ± 22 (range <1 to 88) years and 580 were male (70%). A total of 156 (19%) were under the age of 21 years. Connective tissue diagnoses such as Marfan syndrome were present in 123 (15%). Unaffected participants included relatives (N = 176) and healthy aorta tissue controls (N = 37). Aortic or aortic valve biospecimens were acquired from over 290 and 110 participants, respectively. RNA and protein were extracted from cultured aortic smooth muscle cells (SMCs) for 90 participants. Over 1000 aliquots of aortic SMCs were cryopreserved. The CHAR's breadth, robust biospecimen processing, and phenotyping create a unique, multipronged resource to accelerate our understanding of human aortopathy.

胸主动脉瘤(TAA)是一种发病率和死亡率高的遗传性主动脉疾病,儿童和成人均可发病。遗传原因、病理生物学机制和预后标志物尚不完全清楚。2015年,协作人类主动脉疾病储存库(CHAR)的创建就是为了解决这些根本性的差距。有胸主动脉病变、相关遗传诊断或主动脉瓣疾病的患者符合前瞻性入选条件。家庭成员和控制组也被登记。收集详细的临床和家庭数据,并处理血液和主动脉组织生物标本以供广泛使用。共有1047名参与者被纳入研究。834名受影响参与者的平均年龄为47±22岁(范围N = 176),健康主动脉组织对照组(N = 37)。主动脉或主动脉瓣生物标本分别来自290名和110名参与者。从培养的90名受试者的主动脉平滑肌细胞(SMCs)中提取RNA和蛋白质。超低温保存了1000多份主动脉间充质干细胞。CHAR的广度、强大的生物标本处理和表型分析创造了一个独特的、多管齐下的资源,以加速我们对人类主动脉病变的理解。
{"title":"A Novel Human Biospecimen Repository for Clinical and Molecular Investigation of Thoracic Aortopathy.","authors":"Courtney E Vujakovich,&nbsp;Benjamin J Landis","doi":"10.3390/cardiogenetics11030017","DOIUrl":"https://doi.org/10.3390/cardiogenetics11030017","url":null,"abstract":"<p><p>Thoracic aortic aneurysm (TAA) is a heritable aortopathy with significant morbidity and mortality, affecting children and adults. Genetic causes, pathobiological mechanisms, and prognostic markers are incompletely understood. In 2015, the Collaborative Human Aortopathy Repository (CHAR) was created to address these fundamental gaps. Patients with thoracic aortopathy, associated genetic diagnoses, or aortic valve disease are eligible for prospective enrollment. Family members and controls are also enrolled. Detailed clinical and family data are collected, and blood and aortic tissue biospecimens are processed for broad usage. A total of 1047 participants were enrolled. The mean age in 834 affected participants was 47 ± 22 (range <1 to 88) years and 580 were male (70%). A total of 156 (19%) were under the age of 21 years. Connective tissue diagnoses such as Marfan syndrome were present in 123 (15%). Unaffected participants included relatives (<i>N</i> = 176) and healthy aorta tissue controls (<i>N</i> = 37). Aortic or aortic valve biospecimens were acquired from over 290 and 110 participants, respectively. RNA and protein were extracted from cultured aortic smooth muscle cells (SMCs) for 90 participants. Over 1000 aliquots of aortic SMCs were cryopreserved. The CHAR's breadth, robust biospecimen processing, and phenotyping create a unique, multipronged resource to accelerate our understanding of human aortopathy.</p>","PeriodicalId":41330,"journal":{"name":"Cardiogenetics","volume":"11 3","pages":"148-163"},"PeriodicalIF":0.6,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39606060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Cardiogenetics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1